U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07106671) titled 'A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma' on July 30.
Brief Summary: This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.
Study Start Date: Aug. 10
Study Type: INTERVENTIONAL
Condition:
CRS - Cytokine Release Syndrome
Myeloma
Intervention:
DRUG: Siltuximab
Siltuximab 11mg/kg
Recruitment Status: RECRUITING
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Disclaimer: Curated by HT Syndication....